Functional capacity as assessed by 6-minute walk test distance (6MWTD) has been shown to predict outcomes in selected cohorts with cardiovascular disease. To evaluate the association between 6MWTD and outcomes after transcatheter aortic valve implantation (TAVI) among participants in the Placement of AoRTic TraNscathetER valve (PARTNER) trial, TAVI recipients (n = 484) were stratified into 3 groups according to baseline 6MWTD: unable to walk (n = 218), slow walkers (n = 133), in whom 6MWTD was below the median (128.5 meters), and fast walkers (n = 133) with 6MWTD >128.5 meters. After TAVI, among fast walkers, follow-up 6MWTD decreased by 44 ± 148 meters at 12 months (p <0.02 compared with baseline). In contrast, among slow walkers, 6MWTD improved after TAVI by 58 ± 126 meters (p <0.001 compared with baseline). Similarly, among those unable to walk, 6MWTD distance increased by 66 ± 109 meters (p <0.001 compared with baseline). There were no differences in 30-day outcomes among 6MWTD groups. At 2 years, the rate of death from any cause was 42.5% in those unable to walk, 31.2% in slow walkers, and 28.8% in fast walkers (p = 0.02), driven primarily by differences in noncardiac death. In conclusion, among high-risk older adults undergoing TAVI, baseline 6MWTD does not predict procedural outcomes but does predict long-term mortality. Nonetheless, patients with poor baseline functional status exhibit the greatest improvement in 6MWTD. Additional work is required to identify those with poor functional status who stand to benefit the most from TAVI.
Transcatheter aortic valve implantation (TAVI) is an established treatment for severe symptomatic aortic stenosis (AS) in older adults considered to be inoperable or at high risk for traditional surgery. However, intermediate to long-term mortality rates among patients undergoing TAVI have been high, largely reflecting underlying comorbidities of the treated population. Accordingly, identifying those who stand to benefit the most from TAVI is a priority. The 6-minute walk test distance (6MWTD) is a widely accepted measure of exercise capacity and functional status ; it correlates with peak oxygen consumption and predicts mortality after aortic valve replacement, after coronary revascularization, and in chronic heart failure. Accordingly, we sought to evaluate the prognostic value of 6MWTD among older adults considered to be inoperable or at high surgical risk who received TAVI in the Placement of AoRTic TraNscathetER Valve (PARTNER) Trial. Our primary objectives were (1) to evaluate the association between baseline 6MWTD and functional improvement after TAVI and (2) to evaluate the association between baseline 6MWTD and mortality after TAVI. We hypothesized that those with poor 6MWTD performance at baseline would experience less improvement in functional capacity and would have higher mortality after TAVI.
Methods
The design and initial results of the PARTNER trial have been published previously. The PARTNER trial enrolled patients with severe symptomatic AS. Patients were divided into 2 cohorts: those who were considered to be candidates for surgery despite being at high surgical risk (cohort A) and those who were not considered to be suitable candidates for surgery because of severe coexisting conditions (cohort B). Patients in cohort B with a suitable iliofemoral vessel were randomized to transfemoral TAVI with the Edwards-Sapien heart valve system (Edwards Lifesciences, Irvine, California) or to standard medical care. Patients in cohort A were randomized to TAVI (transfemoral if iliofemoral vessels were suitable or transapical if not) or to conventional surgical aortic valve replacement. The current analyses pooled patients from cohorts A and B who underwent TAVI via a transfemoral or transapical approach. The study was approved by the institutional review board at each participating site, and all patients provided written informed consent.
The 6-minute walk test was attempted at baseline and then at 1, 6, and 12 months after TAVI. It was conducted according to a standardized protocol, using an internal hallway with the 50-foot distance marked. Participants were told that “the purpose of this test is to see how far you can walk in 6 minutes.” They were then instructed to “walk from end to end of the hallway at your own pace, in order to cover as much ground as possible.” Participants were allowed to stop and rest during the test but were instructed to resume walking as soon as they were able to do so. The technician counted the number of laps completed and used a timer to stop the participant 6 minutes after the walk started.
The primary functional outcome was follow-up 6MWTD at 1, 6, and 12 months after TAVI. All available follow-up 6MWTD data were included in this analysis without imputation for those with missing data due to death or failure to return for follow-up visits. The primary clinical outcome measure was the time to death from any cause over 2-years of follow-up. Other clinical outcomes of interest included the 30-day frequency of death from cardiac cause, repeat hospitalization due to AS or complications of the valve procedure, stroke, major bleeding, major vascular complications, permanent pacemaker, and renal failure requiring dialysis. Cardiac death, stroke, and major vascular complications were defined according to a modified version of the Valve Academic Research Consortium criteria as described in the PARTNER trial protocol. The 2-year rates of cardiovascular death and noncardiac death were also analyzed. All events were adjudicated by an independent clinical events committee.
All statistical analyses were based on the population of patients who actually received TAVI. Continuous variables are summarized as median (interquartile range) and were compared using the Mann-Whitney rank-sum test. Categorical variables are presented as proportions and were compared by the chi-square test. The 6MWTD was analyzed as a continuous and categorical variable. Those subjects for whom there was documentation that they were unable to perform the 6-minute walk test were categorized as “unable to walk” and assigned a distance of 0 meters. Otherwise, subjects without 6MWTD at baseline were considered missing and excluded from this analysis. For categorical analyses, baseline 6MWTD was categorized into a 3-level variable: those unable to walk, those with 6MWTD less than or equal to the median value among patients with 6MWTD >0 (128.5 meters, “slow”), and those with 6MWTD greater than the median value (“fast”). To evaluate the change in 6MWTD over time according to baseline 6MWTD group, follow-up 6MWTD at 1, 6, and 12 months were compared with the patient’s baseline distance using paired t test. Between-group comparisons of 6MWTD distances according to baseline 6MWTD groups (unable/slow/fast) were performed using analysis of variance followed by comparisons of individual groups using t tests with Tukey correction.
Thirty-day event rates were compared between groups; only unadjusted analyses were performed to evaluate the association between baseline 6MWTD category and 30-day clinical outcomes. Time to event variables, including death from any cause, noncardiac death, and cardiac death were summarized by means of Kaplan-Meier estimates and compared with the log-rank test. Cox proportional hazards models were used to evaluate the independent association between baseline 6MWTD and all-cause mortality. Multivariable models were built to avoid overfitting using a ratio of 1 covariate for every 10 events. Variables of clinical interest or that satisfied an entry criterion of p <0.1 in the univariate analysis were selected as candidate variables for multivariable models. A 2-sided alpha level of 0.05 was used for all significance testing. All statistical analyses were performed with the use of SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
Results
Among the 699 participants enrolled in the PARTNER trial cohort A and the 358 participants enrolled in the PARTNER trial cohort B, 322 participants from cohort A and 162 from cohort B received TAVI and attempted the 6-minute walk test at baseline and therefore were included in this analysis (n = 484). Among the 484 participants, 218 (124 from cohort A and 94 from cohort B) were unable to perform the 6-minute walk test at baseline and were categorized as “unable” to walk. Among the patients who were able to perform the 6-minute walk test at baseline, the median 6MWTD was 128.5 meters, and the mean 6MWTD was 155.7 ± 110.8 ( Figure 1 ). Of these patients, 133 (94 from cohort A and 39 from cohort B) were categorized as “slow” walkers based on a baseline 6MWTD of ≤128.5 meters, and 133 (104 from cohort A and 29 from cohort B) were categorized as “fast” walkers based on a 6MWTD of >128.5 meters.
Baseline demographic, clinical, and echocardiographic characteristics stratified by baseline 6MWTD are summarized in Table 1 . Notably, those unable to walk were more likely to be women, have higher Society of Thoracic Surgery scores, were less likely to have previous coronary bypass surgery and carotid artery disease, and were more likely to have undergone previous balloon aortic valvuloplasty. The proportion of those with oxygen-dependent chronic obstructive pulmonary disease was highest among those unable to walk and lowest among those who were categorized as fast walkers.
| Variable | Unable to Walk | Slow Walkers | Fast Walkers | p Value |
|---|---|---|---|---|
| Age (yrs) | 84.6 (79.1–88.9) | 85.9 (81.7–88.5) | 83.6 (78.3–87.6) | 0.01 |
| Male gender | 98 (45%) | 73 (55%) | 89 (67%) | 0.0003 |
| Body mass index (kg/m 2 ) | 26.2 (22.7–30.4) | 26.0 (22.1–30.2) | 25.5 (22.8–29.0) | 0.60 |
| Transfemoral TAVI | 180 (83%) | 104 (78%) | 103 (77%) | 0.43 |
| STS Score | 11.4 (10.0–14.0) | 11.1 (9.4–14.0) | 10.5 (8.8–12.0) | 0.001 |
| Diabetes mellitus | 90 (41%) | 46 (35%) | 56 (42%) | 0.37 |
| Hypertension | 193 (89%) | 116 (87%) | 119 (90%) | 0.83 |
| Angina pectoris | 45 (21%) | 37 (28%) | 37 (28%) | 0.19 |
| Heart failure | 216 (99%) | 130 (98%) | 128 (96%) | 0.19 |
| NYHA Class IV | 118 (54%) | 64 (48%) | 60 (45%) | 0.23 |
| CAD | 148 (68%) | 96 (72%) | 103 (77%) | 0.15 |
| Previous PCI | 61 (28%) | 45 (34%) | 39 (29%) | 0.53 |
| Previous coronary bypass | 78 (36%) | 46 (35%) | 64 (48%) | 0.04 |
| Cerebrovascular disease | 59 (29%) | 32 (26%) | 43 (34%) | 0.37 |
| Peripheral vascular disease | 91 (42%) | 49 (37%) | 47 (36%) | 0.47 |
| Previous BAV | 32 (15%) | 23 (17%) | 8 (6%) | 0.01 |
| Permanent pacemaker | 37 (17%) | 37 (29%) | 25 (19%) | 0.04 |
| Renal disease | 41 (19%) | 24 (18%) | 23 (17%) | 0.94 |
| Liver disease | 5 (2%) | 1 (1%) | 8 (6%) | 0.03 |
| Oxygen-dependent COPD | 41 (19%) | 15 (11%) | 10 (8%) | 0.007 |
| AV mean gradient (mm Hg) | 41.9 (32.5–53.3) | 40.4 (33.0–51.2) | 41.3 (33.3–49.2) | 0.67 |
| AV area (EOA) (cm 2 ) | 0.63 (0.51–0.76) | 0.63 (0.53–0.73) | 0.66 (0.56–0.79) | 0.26 |
| Ejection fraction (%) | 55.4 (44.4–61.7) | 53.0 (37.6–61.3) | 57.5 (48.5–64.4) | 0.06 |
| Severe mitral regurgitation | 3 (1%) | 6 (5%) | 6 (5%) | 0.14 |
Mean 6MWTD at baseline and follow-up stratified by baseline category is summarized in Figure 2 . Baseline mean 6MWTD was 240 ± 96 meters among the fast walkers and 72 ± 34 meters among the slow walkers. After TAVI, among fast walkers, follow-up 6MWTD decreased by 53 ± 148 meters (n = 124), 31 ± 136 meters (n = 116), and 44 ± 148 meters (n = 103) at 1, 6, and 12 months, respectively (p <0.02 for all comparisons to baseline). In contrast, among slow walkers, 6MWTD improved after TAVI by 53 ± 118 meters (n = 129), 69 ± 121 meters (n = 116), and 58 ± 126 meters (n = 103) at 1, 6, and 12 months, respectively (all p <0.001 compared with baseline). Similarly, among those unable to walk, 6MWTD increased by 38 ± 80 meters (n = 187), 56 ± 101 meters (n = 164), and 66 ± 109 (n = 139) meters at 1, 6, and 12 months, respectively (all p <0.001 compared with baseline). Figure 3 depicts the pairwise comparison of 6MWTD at baseline and 12 months for all available pairs. The trajectory of 6MWTD over time was heterogeneous in all 3 groups.
At 30 days, there were no differences in rates of major adverse clinical events including death, cardiac death, stroke, or repeat hospitalization according to baseline 6MWTD categories ( Table 2 ). At 2 years, the rate of death from any cause was 42.5% among those unable to walk at baseline, 31.2% among slow walkers at baseline, and 28.8% among fast walkers at baseline (p = 0.016; Figure 4 ). This difference in all-cause mortality was driven primarily by differences in noncardiac death. At 2 years, the rates of noncardiac death were 33.1%, 20.9%, and 19.4% among unable, slow, and fast walkers at baseline (p = 0.009, Figure 4 ), whereas rates of cardiac death were 14.1%, 13.0%, and 11.6% for the same 6MWTD categories (p = 0.77, Figure 4 ).
| 30 Day | ||||
|---|---|---|---|---|
| Unable to Walk | Slow Walkers | Fast Walkers | p Value | |
| Death | ||||
| Any cause | 15 (7%) | 4 (3%) | 6 (5%) | 0.26 |
| Cardiovascular cause | 11 (5%) | 4 (3%) | 4 (3%) | 0.51 |
| Repeat hospitalization ∗ | 12 (6%) | 10 (8%) | 7 (5%) | 0.68 |
| Major stroke | 5 (2%) | 1 (1%) | 1 (1%) | 0.57 |
| Major bleeding | 30 (14%) | 18 (14%) | 15 (11%) | 0.76 |
| Major vascular complications | 31 (14%) | 12 (9%) | 13 (10%) | 0.25 |
| Permanent pacemaker | 5 (2%) | 5 (4%) | 9 (7%) | 0.11 |
| Renal failure (dialysis required) | 8 (4%) | 3 (2%) | 3 (2%) | 0.64 |
Table 3 summarizes the results of multivariable analysis to assess the prognostic significance of baseline 6MWTD in the study population. After adjustment for age, gender, body mass index, history of carotid artery disease, previous balloon aortic valvuloplasty, chronic liver disease, oxygen-dependent chronic obstructive pulmonary disease, Society of Thoracic Surgery risk score, and access route (transfemoral vs transapical), inability to perform the 6-minute walk test at baseline was associated with an increased risk of 2-year death compared with fast walkers (adjusted hazard ratio [HR] 1.80, 95% confidence interval [CI] 1.20 to 2.69; p = 0.004). In contrast, slow walking at baseline was not associated with an increased risk of 2-year mortality compared with fast walking (adjusted HR 1.24, 95% CI 0.78 to 1.95; p = 0.36). A similar relationship was seen when baseline 6MWTD was modeled as a continuous variable (adjusted HR 1.14 per 50 meter decrease in baseline 6MWTD, 95% CI 1.01 to 1.28, p = 0.04). There was no statistically significant interaction between access route (transfemoral vs transapical) and baseline 6MWTD.
